Novartis Femara label update
Executive Summary
Novartis Femara (letrozole) label updated to include survival data in first-line breast cancer Jan. 17. Patients on Femara 2.5 mg had an overall survival of 35 months versus 32 months for tamoxifen 20 mg patients. Median duration of objective response for Femara patients was 18 months compared to 16 months for tamoxifen patients...